Advanced searches left 3/3

Malignant Mesothelioma - Crossref

Summarized by Plex Scholar
Last Updated: 23 January 2023

* If you want to update the article please login/register

A Rare Case of Primary Malignant Pericardial Mesothelioma Diagnosed with Pericardiotomy

Primary malignant pericardial mesothelioma is a rare and lethal cardiac tumor. This paper describes a 62-year-old man with persistent pericardial fluid. Pericardiotomy was used to diagnose and improve the patient's signs, but the procedure was unsuccessful because the pericardium was densely adherent to the myocardium. We recommend adjuvant therapy for the patient with cis-platinum and pexed; however, the patient and his family refused to participate in therapy; however, the patient and his family received no such medicine. The patient's symptoms improved, according to this article, and the patient lived longer than average survivors after surgical surgery. Conclusion: The definitive diagnosis of PMPM has been mainly obtained from specimens obtained by surgery.

Source link: https://doi.org/10.1532/hsf.5047


Identification of Highly Sensitive Pleural Effusion Protein Biomarkers for Malignant Pleural Mesothelioma by Affinity-Based Quantitative Proteomics

Malignant pleural mesothelioma is an asbestos-associated, highly aggressive disease characterized by late-stage diagnosis and poor prognosis. As a result, the testing of PE biomarkers is considered a useful and objective diagnostic device for MPM diagnosis. A prospective cohort of 84 patients referred to thoracoscopy due to medical suspicion of MPM, we used a novel affinity-enrichment mass spectrometry-based proteomics approach for explorative analysis of pleural effusions from a prospective cohort of 84 patients. Protein biomarkers with a high ability to distinguish MPM from non-MPM patients were discovered, and a Random Forest algorithm was used to create classification models. MPM was identified in 40 patients and ruled out MPM in 44 patients, according to Immunohistology of pleural biopsies. Proteomic investigation of pleural effusions revealed panels of proteins with excellent diagnostic capabilities depending on the protein mixture selected. In addition, we also announced previously reported diagnostic accuracy of the MPM markers fibulin-3 and mesothelin measured by two separate mass spectrometry-based techniques.

Source link: https://doi.org/10.3390/cancers15030641


Comparative Immunohistochemical Analysis of IMP3, GLUT1, EMA, CD146, and Desmin for Distinguishing Malignant Mesothelioma From Reactive Mesothelial Cells

Abstract Objectives: To distinguish between malignant mesothelioma and reactive mesothelial cells, it is necessary to identify useful biomarkers for differentiating between malignant mesothelioma and reactive mesothelial cells. EMA had a significantly lower percentage of sarcomatoid MM than did IMP3, GLUT1, and CD146. IMP3's highest areas were found under receiver operating characteristic curves, followed by GLUT1. When the optimal cutoff points for IMP3 and GLUT1 were used, the sensitivity of IMP3 and GLUT1 for MM was 100 percent, and the specificity of both MM was 95%. Conclusions: IMP3 and GLUT1 are the most effective way to distinguish MM from RMC using FFPE sections.

Source link: https://doi.org/10.1309/ajcp5knl7qtellyi


p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer

The aim of this research was to investigate how the p16 FISH assay would be able to distinguish DMPM from RMH and EOC. Methods: p16 FISH was used in 28 DMPMs, 30 RMHs, and 40 EOC cases. P16 FISH's cutoff values were more than 10% for homozygous deletion and more than 40% for heterozygous deletion, with more than 90% being more than 40% for heterozygous deletion. Results: Nine of 19 of 19 successful DMPM cases were homozygous deletion positive, three of 19 were heterozygous deletion positive, and three of 19 were heterozygous deletion positive, with three of 19 of 19 being heterozygous deletion negative, though all RMH cases were negative for the p16 deletion, according to the above criteria. To distinguish DMPM from RMH or EOC, the sensitivity of the p16 homozygous deletion was 32%, and 100% specificity was 100%. Conclusions: Our research shows that when homozygous deletion is detected, p16 FISH analysis is most effective in distinguishing DMPM from RMH and EOC.

Source link: https://doi.org/10.1309/ajcpoatj9l4gcgda


PRAME (Preferentially Expressed Antigen of Melanoma) Is a Novel Marker for Differentiating Serous Carcinoma From Malignant Mesothelioma

Abstract: When compared to malignant mesothelioma using gene expression arrays, the PRAME gene was previously found to be overexpressed in ovarian/primary serous carcinoma. Although survival was unrelated to longevity, PRAME levels in mu00fcllerian carcinoma were not up-regulated in solid metastases compared to primary carcinoma and effusions, compared to primary carcinoma and effusions. Our results show that PRAME effectively distinguishes mu00fcllerian carcinoma from malignant mesothelioma at the mRNA and protein levels, indicating a role in the diagnostic workup of serosal cancers.

Source link: https://doi.org/10.1309/ajcpga95kvsaudmf


Psychosocial well-being among patients with malignant pleural mesothelioma

Patients with malignant pleural mesothelioma performed a series of assessments at a single timepoint after being invited either by appointment or by letter during routine medical oncology clinic visits. Participants endorsed significant elevated depression symptoms, with fourteen percent of participants recommending significantly elevated depression. Depressed participants with no significant demographic or clinical differences were found compared to non-depressed participants, with a trend toward those who identified as Hispanic and those who were divorced being more likely to be depressed. Active coping, emotional assistance, and acceptance were among the most commonly recommended coping techniques for the complete sample. The present study did not find any concrete correlates of depression or QOL among patients with MPM. This research contributes to the tiny body of MPM psychosocial functioning in patients with MPM patients with MPM and provides concise recommendations for future larger studies and the creation of interventions to provide appropriate treatment to diverse patients with MPM.

Source link: https://doi.org/10.1017/s1478951522001596


Usefulness of EMA, GLUT-1, and XIAP for the Cytologic Diagnosis of Malignant Mesothelioma in Body Cavity Fluids

In the distinction between malignant mesothelioma and benign effusion in body cavity fluids, we compared the effectiveness of epithelial membrane antigen with two newly identified markers, X-linked inhibitor of apoptosis protein and an isoform of glucose transporter. Cell block sections from 35 cases of histologically confirmed MM and 38 BEs were used in immunohistochemical experiments, from antibodies to EMA, XIAP, and GLUT-1 were used in immunohistochemical studies. EMA is a more reliable indicator of MM diagnosis than XIAP or GLUT-1 based on these findings.

Source link: https://doi.org/10.1309/ajcpwfw7o1fvflkt


Malignant mesothelioma among US Medicare beneficiaries: incidence, prevalence and therapy, 2016–2019

Patients receiving trimodal therapy have longer lives than those who receive two or fewer therapy options. This report uses 2016-2013 Medicare claims data to determine the prevalence of malignant mesothelioma and identify treatment trends among continuously enrolling fee-for-service beneficiaries. In 2019, the annual incidence of 100 000 beneficiaries ranged from 8. 8 in 2016 to 31. 3 in 2019, with annual incidence per 100 000 beneficiaries ranging from 8. 8 in 2016 to 32. 8 in 2017. According to the mesothelioma case report, 4. 3 percent of patients received chemotherapy alone, 2. 3 percentu20131. 5% underwent radiation alone, and 4. 6 percentu201310. 5% underwent surgical intervention alone, with 4. 6 percent of the population receiving all three therapy modalities. Medicare results build on results from cancer registry studies to increase our understanding of the mesothelioma incidence and therapy patterns.

Source link: https://doi.org/10.1136/oemed-2022-108706


Computational Model for Prediction of Malignant Mesothelioma Diagnosis

Abstract Mesothelioma is a rare lung cancer that damages the linings of the lung linings. This review provides a comparison of several machine learning technologies with different feature sets and addresses the issue of class mismatch. To solve the class disparities, this research used the resampling technique, synthetic minority oversampling technique, and adaptive synthetic sampling to remedy the class imbalance. With the resampling procedure, the majority of the machine learning strategies met well. The highest accuracy was reported on the feature set selected by principal component analysis is 96%. Using SMOTE and ADASYN, the proposed stacking-based classificationifier achieved the highest accuracy on data balance.

Source link: https://doi.org/10.1093/comjnl/bxab146


Cost-effectiveness analysis of first-line nivolumab plus ipilimumab combination therapy for unresectable malignant pleural mesothelioma: based on a multicenter, phase 3 trial

History: Malignant pleural mesothelioma is a rare condition. MPM's approved systemic therapy is limited to chemotherapy. This research was conducted to determine the economic effectiveness of an NIV plus IPI therapy for MPM in China. Methods: The results came from a multicenter randomised phase III trial that revealed an improved survival benefit in patients with MPM treated with a NIV+IPI combination therapy, according to the researchers. The change in effectiveness of 0. 08 QALYs from 1. 08 QALYs to 1. 16 QALYs has been traced to an increase in productivity of 0. 08 QALYs. According to the ICER results predicted by sensitivity analysis, cost changes associated with grade 3-4 AE management, tests conducted, or hospitalization expenditures had no effect on the ICER values estimated by sensitivity analysis. Conclusions: The findings of this research reveal that the combination of NIV plus IPI is not a cost-effective option from Chinese payers' standpoints as a first-line therapy option for MPM patients in China.

Source link: https://doi.org/10.22541/au.167396962.20241995/v1

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions